Answers are grounded in this paper and cite their sources.
Insulin and beta-adrenergic agonists stimulate a rapid phosphorylation and sequestration of the beta2-adrenergic receptors (beta2ARs). Although the expectation was that a common pathway would be involved in the trafficking of the beta2AR in response to either hormone, studies reported herein show the existence of unique cytoskeletal requirements for internalization/recycling of G-protein-coupled receptors, such as the beta2AR. Treatment of human epidermoid carcinoma A431 cells with nocodazole, which binds tubulin monomer in vivo and catalyzes the depolymerization of microtubules, effectively blocks beta-adrenergic agonist-induced, but not insulin-induced, sequestration of beta2ARs. Treatment with latrunculin-A, an agent that sequesters actin monomer and leads to loss of actin filaments, had no effect on the ability of beta-adrenergic agonists to stimulate internalization of beta2ARs, but blocked the ability of insulin to stimulate counterregulation of beta2ARs via internalization. Although nocodazole had no effect on insulin-stimulated sequestration of beta2ARs, the recycling of the internalized receptors to the cell membrane was sensitive to depolymerization of microtubules by this agent. Latrunculin-A, by contrast, blocks the recycling of beta2ARs internalized in response to beta-agonist, while attenuating recycling of receptors internalized in response to insulin stimulation. These data show the existence of unique cytoskeletal requirements for G-protein-coupled-receptor trafficking in response to agonist compared with a counterregulatory hormone, and for sequestration versus recycling of the receptors to the cell membrane.
No takes yet. Share an insight, caveat, or question.
Shumay et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: